S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.64 (-1.44%)
MSFT   400.51 (-0.93%)
META   484.41 (-3.47%)
GOOGL   154.09 (-1.23%)
AMZN   175.53 (-2.06%)
TSLA   149.51 (-0.28%)
NVDA   811.76 (-4.13%)
AMD   148.70 (-4.11%)
NIO   3.84 (-4.00%)
BABA   68.63 (-0.36%)
T   16.34 (+0.06%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   149.14 (-2.48%)
CGC   7.98 (+1.92%)
DIS   111.55 (-0.78%)
AMC   3.24 (+10.96%)
PFE   25.85 (+1.81%)
PYPL   62.03 (-0.11%)
XOM   120.11 (+1.34%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.64 (-1.44%)
MSFT   400.51 (-0.93%)
META   484.41 (-3.47%)
GOOGL   154.09 (-1.23%)
AMZN   175.53 (-2.06%)
TSLA   149.51 (-0.28%)
NVDA   811.76 (-4.13%)
AMD   148.70 (-4.11%)
NIO   3.84 (-4.00%)
BABA   68.63 (-0.36%)
T   16.34 (+0.06%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   149.14 (-2.48%)
CGC   7.98 (+1.92%)
DIS   111.55 (-0.78%)
AMC   3.24 (+10.96%)
PFE   25.85 (+1.81%)
PYPL   62.03 (-0.11%)
XOM   120.11 (+1.34%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.64 (-1.44%)
MSFT   400.51 (-0.93%)
META   484.41 (-3.47%)
GOOGL   154.09 (-1.23%)
AMZN   175.53 (-2.06%)
TSLA   149.51 (-0.28%)
NVDA   811.76 (-4.13%)
AMD   148.70 (-4.11%)
NIO   3.84 (-4.00%)
BABA   68.63 (-0.36%)
T   16.34 (+0.06%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   149.14 (-2.48%)
CGC   7.98 (+1.92%)
DIS   111.55 (-0.78%)
AMC   3.24 (+10.96%)
PFE   25.85 (+1.81%)
PYPL   62.03 (-0.11%)
XOM   120.11 (+1.34%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.64 (-1.44%)
MSFT   400.51 (-0.93%)
META   484.41 (-3.47%)
GOOGL   154.09 (-1.23%)
AMZN   175.53 (-2.06%)
TSLA   149.51 (-0.28%)
NVDA   811.76 (-4.13%)
AMD   148.70 (-4.11%)
NIO   3.84 (-4.00%)
BABA   68.63 (-0.36%)
T   16.34 (+0.06%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   149.14 (-2.48%)
CGC   7.98 (+1.92%)
DIS   111.55 (-0.78%)
AMC   3.24 (+10.96%)
PFE   25.85 (+1.81%)
PYPL   62.03 (-0.11%)
XOM   120.11 (+1.34%)
Free Trial
NASDAQ:STSA

Satsuma Pharmaceuticals (STSA) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)
Free STSA Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.01
▼
$1.14
50-Day Range
$1.04
▼
$1.11
52-Week Range
$0.59
▼
$8.08
Volume
1.83 million shs
Average Volume
701,788 shs
Market Capitalization
$36.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
STSA stock logo

About Satsuma Pharmaceuticals Stock (NASDAQ:STSA)

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

STSA Stock News Headlines

August 30, 2023 | usnews.com
Satsuma City High School
June 9, 2023 | bizjournals.com
Japanese pharma acquires its crash-strapped Durham spin-out
April 19, 2024 | Darwin (Ad)
Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report
Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)
June 8, 2023 | bizjournals.com
Japanese pharma acquires its Durham spin-out
May 18, 2023 | finance.yahoo.com
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
May 3, 2023 | marketwatch.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRA
May 1, 2023 | benzinga.com
Shareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nippon
April 25, 2023 | marketwatch.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRA
April 19, 2024 | The Bull Report (Ad)
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
April 22, 2023 | seekingalpha.com
STSA Satsuma Pharmaceuticals, Inc.
April 21, 2023 | finance.yahoo.com
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
April 19, 2023 | msn.com
After Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More Upside
April 18, 2023 | marketwatch.com
Satsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSA
April 17, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. Buyout
April 17, 2023 | bizjournals.com
Peninsula company bets big part of potential $221M sale on future of migraine drug
April 17, 2023 | markets.businessinsider.com
Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical
April 17, 2023 | msn.com
Satsuma Skyrockets after Acquisition by Shin Nippon
April 17, 2023 | investorplace.com
Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?
April 16, 2023 | finance.yahoo.com
SNBL to Acquire Satsuma Pharmaceuticals
March 30, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)
March 30, 2023 | finance.yahoo.com
We're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Rate
March 29, 2023 | bizjournals.com
Migraine drug maker seeks FDA approval and a partner as it cuts jobs
March 28, 2023 | finance.yahoo.com
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 18, 2023 | marketwatch.com
8-K: Satsuma Pharmaceuticals, Inc.
February 7, 2023 | reuters.com
STSA.O
February 2, 2023 | finance.yahoo.com
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
December 28, 2022 | finance.yahoo.com
Despite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For Approval
See More Headlines
Receive STSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Regional Banks
Current Symbol
NASDAQ:STSA
CUSIP
85931930
CIK
891106
Web
www.satsumarx.com
Phone
650-410-3200
Fax
N/A
Employees
21
Year Founded
2016

Profitability

EPS (Most Recent Fiscal Year)
($2.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-70,060,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-115.24%
Return on Assets
-102.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.44
Quick Ratio
7.44

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
0.78

Miscellaneous

Outstanding Shares
33,150,000
Free Float
22,809,000
Market Cap
$36.47 million
Optionable
Not Optionable
Beta
0.10

Social Links

Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. John A. Kollins MBA (Age 59)
    Pres, CEO & Director
    Comp: $830k
  • Mr. Thomas P. O'Neil (Age 57)
    Chief Financial Officer
    Comp: $550.08k
  • Dr. Detlef F. Albrecht (Age 61)
    Chief Medical Officer
    Comp: $625.97k
  • Mr. Mic Iwashima (Age 44)
    VP & Head of Operations
  • Mr. Robert Schultz (Age 58)
    Sr. VP & Head of Chemistry, Manufacturing and Controls
  • Dr. Shannon Strom Ph.D. (Age 46)
    VP & Head of Regulatory Affairs
  • Mr. Robert M. Janosky
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders


STSA Stock Analysis - Frequently Asked Questions

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) issued its earnings results on Tuesday, November, 9th. The financial services provider reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.09.

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).

When did Satsuma Pharmaceuticals IPO?

Satsuma Pharmaceuticals (STSA) raised $75 million in an initial public offering on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

This page (NASDAQ:STSA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
My biggest AI fear
Paradigm Press
Options trading has suddenly become more reliable.
Eagle Publishing